
National Peroxide (NPL) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
666.6M
Gross Profit
339.1M
50.87%
Operating Income
-3.1M
-0.46%
Net Income
8.9M
1.34%
EPS (Diluted)
₹1.55
Balance Sheet Metrics
Total Assets
4.4B
Total Liabilities
924.6M
Shareholders Equity
3.5B
Debt to Equity
0.26
Cash Flow Metrics
Operating Cash Flow
59.8M
Free Cash Flow
23.9M
Revenue & Profitability Trend
National Peroxide Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 2.9B | 3.3B | 3.8B | 0 | 0 |
Cost of Goods Sold | 1.5B | 1.6B | 1.9B | 0 | 0 |
Gross Profit | 1.4B | 1.7B | 1.9B | 0 | 0 |
Gross Margin % | 48.3% | 51.7% | 50.6% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 159.1M | 125.3M | 83.0K | 30.0K |
Other Operating Expenses | 931.1M | 1.1B | 919.8M | - | 2.0K |
Total Operating Expenses | 931.1M | 1.2B | 1.0B | 83.0K | 32.0K |
Operating Income | -49.0M | 183.3M | 401.5M | -83.0K | -32.0K |
Operating Margin % | -1.7% | 5.5% | 10.7% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | - | 5.1M | 181.0K | 0 | 0 |
Interest Expense | 16.7M | 19.8M | 48.3M | 0 | 0 |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -20.8M | 215.1M | 535.0M | -83.0K | -72.0K |
Income Tax | 1.7M | 47.2M | 140.0M | 0 | 0 |
Effective Tax Rate % | 0.0% | 22.0% | 26.2% | 0.0% | 0.0% |
Net Income | -22.5M | 167.9M | 395.0M | -83.0K | -72.0K |
Net Margin % | -0.8% | 5.0% | 10.5% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | 197.0M | 427.5M | 637.3M | -83.0K | -72.0K |
EPS (Basic) | ₹-3.91 | ₹29.22 | ₹68.73 | ₹-0.01 | ₹-0.01 |
EPS (Diluted) | ₹-3.91 | ₹29.22 | ₹68.73 | ₹-0.01 | ₹-0.01 |
Basic Shares Outstanding | 5745269 | 5747000 | 5747000 | 5747000 | 5747000 |
Diluted Shares Outstanding | 5745269 | 5747000 | 5747000 | 5747000 | 5747000 |
Income Statement Trend
National Peroxide Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 129.3M | 86.1M | 64.3M | 21.0K | 100.0K |
Short-term Investments | 505.5M | 431.3M | 399.6M | - | - |
Accounts Receivable | 228.1M | 271.5M | 242.7M | 0 | 0 |
Inventory | 324.9M | 338.5M | 361.5M | 0 | 0 |
Other Current Assets | 20.4M | - | - | - | - |
Total Current Assets | 1.2B | 1.2B | 1.1B | 21.0K | 100.0K |
Non-Current Assets | |||||
Property, Plant & Equipment | 3.1B | 0 | 0 | 0 | - |
Goodwill | 5.0M | 310.0K | 2.4M | 0 | 0 |
Intangible Assets | - | 310.0K | 2.4M | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 4.4M | - | - | - | - |
Total Non-Current Assets | 3.2B | 3.4B | 3.4B | 0 | 0 |
Total Assets | 4.4B | 4.6B | 4.5B | 21.0K | 100.0K |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 198.0M | 223.3M | 230.6M | 76.0K | 72.0K |
Short-term Debt | 3.4M | 37.0M | 37.8M | 0 | 0 |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 29.8M | - | - | - | - |
Total Current Liabilities | 366.2M | 408.9M | 405.2M | 76.0K | 72.0K |
Non-Current Liabilities | |||||
Long-term Debt | 122.1M | 160.4M | 196.4M | 0 | 0 |
Deferred Tax Liabilities | 397.3M | 402.0M | 382.3M | 0 | 0 |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 558.4M | 594.7M | 610.3M | 0 | 0 |
Total Liabilities | 924.6M | 1.0B | 1.0B | 76.0K | 72.0K |
Equity | |||||
Common Stock | 57.5M | 57.5M | 57.5M | 100.0K | 100.0K |
Retained Earnings | - | 467.1M | 397.4M | -155.0K | -72.0K |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 3.5B | 3.6B | 3.5B | -55.0K | 28.0K |
Key Metrics | |||||
Total Debt | 125.5M | 197.4M | 234.2M | 0 | 0 |
Working Capital | 842.0M | 791.5M | 730.9M | -55.0K | 28.0K |
Balance Sheet Composition
National Peroxide Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -20.8M | 215.1M | 535.0M | -83.0K | -72.0K |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 60.8M | 38.1M | -113.8M | 0 | 0 |
Operating Cash Flow | 50.1M | 267.9M | 491.3M | -83.0K | -72.0K |
Investing Activities | |||||
Capital Expenditures | -42.4M | -144.1M | -56.7M | 0 | 0 |
Acquisitions | - | - | - | - | - |
Investment Purchases | -883.8M | -778.7M | -2.1B | 0 | 0 |
Investment Sales | 902.5M | 742.5M | 2.4B | 0 | 0 |
Investing Cash Flow | -23.6M | -180.3M | 247.7M | 0 | 0 |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -71.8M | -100.6M | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | -35.3M | -35.3M | -796.6M | 0 | 0 |
Financing Cash Flow | -107.1M | -136.2M | -796.3M | 0 | 100.0K |
Free Cash Flow | 137.8M | 217.7M | 611.2M | -79.0K | 0 |
Net Change in Cash | -80.7M | -48.5M | -57.4M | -83.0K | 28.0K |
Cash Flow Trend
National Peroxide Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
47.40
Price to Book
1.04
Price to Sales
1.30
PEG Ratio
-0.42
Profitability Ratios
Profit Margin
-2.30%
Operating Margin
-0.46%
Return on Equity
-0.64%
Return on Assets
-0.51%
Financial Health
Current Ratio
3.30
Debt to Equity
3.59
Per Share Data
EPS (TTM)
₹-11.21
Book Value per Share
₹607.57
Revenue per Share
₹486.57
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
npl | 3.6B | 47.40 | 1.04 | -0.64% | -2.30% | 3.59 |
Asian Paints | 2.4T | 65.93 | 12.25 | 18.28% | 10.63% | 11.42 |
Pidilite Industries | 1.6T | 71.77 | 16.03 | 20.85% | 16.16% | 4.56 |
Balaji Amines | 49.9B | 32.81 | 2.71 | 7.80% | 11.11% | 0.55 |
Camlin Fine Sciences | 40.4B | 57.31 | 4.48 | -15.89% | -6.73% | 77.88 |
Grauer & Weil | 43.4B | 27.61 | 4.62 | 18.02% | 13.85% | 1.26 |
Financial data is updated regularly. All figures are in the company's reporting currency.